{"nctId":"NCT01991795","briefTitle":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2014-02-10","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":19271,"armGroups":[{"label":"Ticagrelor 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ticagrelor 60 mg"]},{"label":"Ticagrelor placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Ticagrelor placebo"]}],"interventions":[{"name":"Ticagrelor 60 mg","otherNames":["Brilinta/Brilique"]},{"name":"Ticagrelor placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMen or women â‰¥50 years of age with type 2 diabetes mellitus on treatment with a glucose lowering medication since at least 6 months, and either documented coronary artery occlusive disease or previous revascularization of a coronary artery.\n\nKey Exclusion Criteria:\n\nHistory of myocardial infarction or any stroke; planned treatment with agents inhibiting blood clotting; planned use of ASA/Aspirin at doses above 150 mg daily; planned coronary, cerebrovascular, or peripheral arterial revascularization; patients with known bleeding disorders and patients who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin; history of intracranial bleeding at any time, or a history of bleeding from the gastrointestinal tract within the last 6 months or a major surgery within the last 30 days; patients with known severe liver disease or with kidney failure requiring dialysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of Cardiovascular (CV) Death, MI or Stroke","description":"Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"736","spread":null},{"groupId":"OG001","value":"818","spread":null}]}]}]},{"type":"SECONDARY","title":"CV Death","description":"Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"364","spread":null},{"groupId":"OG001","value":"357","spread":null}]}]}]},{"type":"SECONDARY","title":"MI","description":"Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null},{"groupId":"OG001","value":"328","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischaemic Stroke","description":"Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Death","description":"Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"579","spread":null},{"groupId":"OG001","value":"592","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"TIMI Major Bleeding Event (Primary Safety Objective)","description":"Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"TIMI Major or Minor Bleeding Event","description":"Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"PLATO Major Bleeding Event","description":"Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Permanent Discontinuation of Study Medication Due to Any Bleeding Event","description":"Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"466","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3049,"n":9562},"commonTop":["Dyspnoea"]}}}